Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
In the last 90 days, Actuate Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $7.13M
- Insider buysLast 90 days, $50.0K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 62
- 13F valueReported value at the end of Q2 2026
- $20.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$22.2M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.30M
- Shares sold short
- Change
- −569.0K
- −30.5% vs. previous
- Days to cover
- 2.12
- At average daily volume
Superinvestors holding ACTU, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ACTU at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Actuate Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 2026 (view filing)9:35 AM ET | Oct 28 | 1 day | Schmitt Daniel MPresident, CEO and Director | PPurchase | +140.8K | $0.355 | +$50.0K | +46.7%442.6K after | |
| Oct 29, 2026 (view filing)9:35 AM ET | Oct 28 | 1 day | Schmitt Daniel MPresident, CEO and Director | PPurchase | +70.4K | $0.00 | $0 | –70.4K after | Derivative |
| Jan 7, 2026 (view filing)12:45 PM ET | Jan 5 | 2 days | Thomson Todd S and 1 otherDirector, 10% Owner | SSale | −280.0K | $5.80 | −$1.62M | −23.6%904.8K after | |
| Jun 30, 2025 (view filing)1:03 PM ET | Jun 27 | 3 days | BP Directors, LP and 3 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | Duplicate filing |
| Jun 30, 2025 (view filing)1:03 PM ET | Jun 27 | 3 days | BP Directors, LP and 3 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | DerivativeDuplicate filing |
| Jun 30, 2025 (view filing)1:02 PM ET | Jun 27 | 3 days | BIOS Fund I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | Duplicate filing |
| Jun 30, 2025 (view filing)1:02 PM ET | Jun 27 | 3 days | BIOS Fund I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | DerivativeDuplicate filing |
| Jun 30, 2025 (view filing)1:01 PM ET | Jun 27 | 3 days | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | |
| Jun 30, 2025 (view filing)1:01 PM ET | Jun 27 | 3 days | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | Derivative |
| Aug 20, 2024 (view filing)8:46 PM ET | Aug 14 | 6 days | BP Directors, LP and 2 othersDirector, 10% Owner | SSale | −25.0K | $8.00 | −$200.0K | −16.0%131.2K after | Amended3 lotsDuplicate filing |
Top 10 13F holders, Q2 2026
See all 62 holdersThe largest institutional positions in Actuate Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 10,049,996 | $15.4M | 36.90% | 00.0% | Unchanged |
| Voss Capital, LLC | 1,725,000 | $2.64M | 0.13% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 393,433 | $602.0K | 0.00% | −7,096−1.8% | Reduced |
| AQR Capital Management LLC | 127,493 | $195.1K | 0.00% | +100,384+370.3% | Added |
| Geode Capital Management, LLC | 112,554 | $172.2K | 0.00% | −115,777−50.7% | Reduced |
| Texas Capital Bank Wealth Management Services Inc | 102,612 | $157.0K | 0.01% | +8,020+8.5% | Added |
| Palogic Value Management, L.P. | 100,000 | $153.0K | 0.05% | 00.0% | Unchanged |
| Millennium Management LLC | 96,684 | $147.9K | 0.00% | +96,684 | New |
| BlackRock, Inc. | 90,035 | $137.8K | 0.00% | −337,118−78.9% | Reduced |
| ABS Investment Management LLC | 73,186 | $112.0K | 0.09% | +73,186 | New |
Holders of 5% or more of ACTU
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Actuate Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BIOS Fund I, LP | 13D/A | 49.80%10.3M shares | −2.60 ppfrom 52.40% | Aug 19, 20243 filings | Jun 30, 2025 | SEC |
| Hexstone Capital LLC | 13G | 7.70%4.23M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |
| Voss Capital, LLC | 13G/A | 7.70%1.81M shares | +2.40 ppfrom 5.30% | Dec 17, 20252 filings | Apr 22, 2026 | SEC |